JP2004510684A - 神経学的疾患の治療のためのアゾアミノ酸誘導体 - Google Patents

神経学的疾患の治療のためのアゾアミノ酸誘導体 Download PDF

Info

Publication number
JP2004510684A
JP2004510684A JP2001507802A JP2001507802A JP2004510684A JP 2004510684 A JP2004510684 A JP 2004510684A JP 2001507802 A JP2001507802 A JP 2001507802A JP 2001507802 A JP2001507802 A JP 2001507802A JP 2004510684 A JP2004510684 A JP 2004510684A
Authority
JP
Japan
Prior art keywords
straight
compound
ring
optionally
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001507802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004510684A5 (enExample
Inventor
ローファー，デイビッド
マリカン，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2004510684A publication Critical patent/JP2004510684A/ja
Publication of JP2004510684A5 publication Critical patent/JP2004510684A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001507802A 1999-07-06 2000-07-05 神経学的疾患の治療のためのアゾアミノ酸誘導体 Pending JP2004510684A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14256999P 1999-07-06 1999-07-06
PCT/US2000/018416 WO2001002362A1 (en) 1999-07-06 2000-07-05 Azo amino acid derivatives for the treatment of neurological diseases

Publications (2)

Publication Number Publication Date
JP2004510684A true JP2004510684A (ja) 2004-04-08
JP2004510684A5 JP2004510684A5 (enExample) 2004-12-24

Family

ID=22500365

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001507802A Pending JP2004510684A (ja) 1999-07-06 2000-07-05 神経学的疾患の治療のためのアゾアミノ酸誘導体

Country Status (5)

Country Link
US (2) US6528533B2 (enExample)
EP (1) EP1196387A1 (enExample)
JP (1) JP2004510684A (enExample)
AU (1) AU6205700A (enExample)
WO (1) WO2001002362A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US7127271B1 (en) 2001-10-18 2006-10-24 Iwao Fujisaki Communication device
US7466992B1 (en) 2001-10-18 2008-12-16 Iwao Fujisaki Communication device
US7107081B1 (en) 2001-10-18 2006-09-12 Iwao Fujisaki Communication device
US8229512B1 (en) 2003-02-08 2012-07-24 Iwao Fujisaki Communication device
US8241128B1 (en) 2003-04-03 2012-08-14 Iwao Fujisaki Communication device
US8090402B1 (en) 2003-09-26 2012-01-03 Iwao Fujisaki Communication device
US7917167B1 (en) 2003-11-22 2011-03-29 Iwao Fujisaki Communication device
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
US8208954B1 (en) 2005-04-08 2012-06-26 Iwao Fujisaki Communication device
CA2637707A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
CN101400367A (zh) * 2006-02-02 2009-04-01 瑞纳神经科学公司 施用trkb激动剂治疗不希望的重量减轻或进食障碍的方法
US7890089B1 (en) 2007-05-03 2011-02-15 Iwao Fujisaki Communication device
US8559983B1 (en) 2007-05-03 2013-10-15 Iwao Fujisaki Communication device
US8676273B1 (en) 2007-08-24 2014-03-18 Iwao Fujisaki Communication device
US8639214B1 (en) 2007-10-26 2014-01-28 Iwao Fujisaki Communication device
US8472935B1 (en) 2007-10-29 2013-06-25 Iwao Fujisaki Communication device
US8744720B1 (en) 2007-12-27 2014-06-03 Iwao Fujisaki Inter-vehicle middle point maintaining implementer
US8543157B1 (en) 2008-05-09 2013-09-24 Iwao Fujisaki Communication device which notifies its pin-point location or geographic area in accordance with user selection
US8340726B1 (en) 2008-06-30 2012-12-25 Iwao Fujisaki Communication device
US8452307B1 (en) 2008-07-02 2013-05-28 Iwao Fujisaki Communication device
BR102015000922B8 (pt) * 2015-01-15 2022-07-12 Fundacao Oswaldo Cruz Compostos a-cetoacílicos de isoniazida, processo de obtenção dos ditos compostos e uso dos compostos no tratamento de tuberculose

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037370A (en) * 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
PL195273B1 (pl) * 1997-08-29 2007-08-31 Vertex Pharma Związki wykazujące aktywność neuronalną, kompozycja farmaceutyczna zawierająca taki związek oraz zastosowanie tych związków

Also Published As

Publication number Publication date
US20020103190A1 (en) 2002-08-01
WO2001002362A1 (en) 2001-01-11
US6528533B2 (en) 2003-03-04
US6716860B2 (en) 2004-04-06
EP1196387A1 (en) 2002-04-17
AU6205700A (en) 2001-01-22
US20030109526A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
JP2004510684A (ja) 神経学的疾患の治療のためのアゾアミノ酸誘導体
JP2004510684A5 (enExample)
PL191249B1 (pl) Farmaceutycznie dopuszczalna kompozycja do stymulowania wzrostu neurytów i zastosowanie pochodnych mocznika lub karbaminianu
US6849630B2 (en) Cyclized amino acid derivatives
US6660748B2 (en) Bicyclic derivatives
US7105546B2 (en) Acyclic and cyclic amine derivatives
JP2006504717A (ja) 神経学的疾患の処置のためのピペラジンおよびピペラジン誘導体
US6552041B2 (en) Cyclized amide derivatives
JP2006504717A5 (enExample)
US20020123493A1 (en) Cyclic amine derivatives
JP2004536085A (ja) ニューロン損傷を処置するのに有用なアシル化ピペラジン誘導体およびピペリジン誘導体
US20020111347A1 (en) Amino-alkyl derivatives
US6677359B2 (en) N-substituted glycine derivatives
US20020123492A1 (en) Beta-amino acid derivatives
US20050065339A1 (en) Amino-alkyl derivatives